To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. (Schedule II controlled substances are substances that have a high potential for abuse but have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.)

Bill 118 hr 1393 aims to make changes to the Controlled Substances Act in order to better define what constitutes currently accepted medical use with severe restrictions. The bill seeks to clarify the regulations surrounding the use of controlled substances for medical purposes, particularly in cases where there are strict limitations on their use.

The proposed legislation would provide a more precise definition of what qualifies as currently accepted medical use with severe restrictions, ensuring that patients who require these substances for legitimate medical reasons are able to access them while also preventing misuse and abuse. The bill also includes provisions for monitoring and regulating the distribution of these substances to ensure they are being used appropriately.

Overall, Bill 118 hr 1393 is aimed at striking a balance between providing access to necessary medications for patients with severe medical conditions while also implementing safeguards to prevent misuse and abuse of controlled substances. It is an important piece of legislation that seeks to address the complexities of regulating controlled substances for medical use in a responsible and effective manner.